{"id":2843,"date":"2026-08-13T12:48:17","date_gmt":"2026-08-13T11:48:17","guid":{"rendered":"https:\/\/seamlessbio.de\/?p=2843"},"modified":"2026-08-13T13:40:44","modified_gmt":"2026-08-13T12:40:44","slug":"fda-ema-mandatory-drug-transporters-ind-dmpk-guide","status":"publish","type":"post","link":"https:\/\/seamlessbio.de\/de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/","title":{"rendered":"FDA &amp; EMA Mandatory Drug Transporters"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><em>August 2026 \u00b7 10 min read<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Before your drug candidate enters first-in-human trials, regulatory agencies expect you to have characterised its interactions with a defined set of drug transporters. Miss one, and you risk a clinical hold, a label restriction, or a post-market safety signal that could have been identified in a 96-well plate. Get it right, and you have a clean DMPK package that supports your IND without questions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This guide covers exactly which transporters FDA, EMA, and ICH M12 require \u2014 and which are recommended but not mandatory \u2014 along with the cutoff values, assay approaches, and decision points that determine whether in vitro data alone is sufficient or whether a clinical DDI study is needed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The regulatory landscape \u2014 three agencies, one aligned framework<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The global regulatory framework for drug transporter DDI assessment is now largely harmonised following the 2022 ICH M12 guideline, which consolidates recommendations from the FDA 2020 DDI guidance and the EMA 2012 DDI guideline. For practical purposes, a transporter package built to ICH M12 standards satisfies FDA, EMA, and PMDA requirements simultaneously.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The key distinction to understand is between <strong>mandatory<\/strong> transporters (required for all new molecular entities, NMEs) and <strong>context-dependent<\/strong> transporters (required only if specific conditions apply \u2014 elimination route, therapeutic indication, co-medication profile).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The mandatory transporter panel \u2014 required for all NMEs<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The following transporters must be assessed for all NMEs during IND-enabling studies. These studies are recommended by both FDA and EMA drug-drug interaction guidelines to evaluate transporter interactions before going into first-in-human trials.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">ABC efflux transporters (vesicle assay)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>P-gp (ABCB1 \/ MDR1)<\/strong> \u2014 intestinal absorption, blood-brain barrier, renal and hepatic efflux. Required by FDA, EMA, ICH M12. Substrate and inhibitor assessment.<\/li>\n\n\n\n<li><strong>BCRP (ABCG2)<\/strong> \u2014 intestinal absorption, hepatic efflux, breast\/placental barrier. Required by FDA, EMA, ICH M12. Substrate and inhibitor assessment.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">SLC uptake transporters (cell-based assay)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>OATP1B1 (SLC01B1)<\/strong> \u2014 hepatic uptake; key determinant of statin and bilirubin pharmacokinetics. Required by FDA, EMA, ICH M12.<\/li>\n\n\n\n<li><strong>OATP1B3 (SLC01B3)<\/strong> \u2014 hepatic uptake; often co-assessed with OATP1B1. Required by FDA, EMA, ICH M12.<\/li>\n\n\n\n<li><strong>OCT2 (SLC22A2)<\/strong> \u2014 renal secretion of cationic drugs; metformin is the clinical probe substrate. Required by FDA, EMA, ICH M12.<\/li>\n\n\n\n<li><strong>OAT1 (SLC22A6)<\/strong> \u2014 renal secretion of anionic drugs; furosemide probe. Required by FDA, EMA, ICH M12.<\/li>\n\n\n\n<li><strong>OAT3 (SLC22A8)<\/strong> \u2014 renal secretion of anionic drugs, often co-assessed with OAT1. Required by FDA, EMA, ICH M12.<\/li>\n\n\n\n<li><strong>MATE1 (SLC47A1)<\/strong> \u2014 renal secretion, apical side; completes the renal cation secretion pathway with OCT2. Required by FDA, EMA, ICH M12.<\/li>\n\n\n\n<li><strong>MATE2-K (SLC47A2)<\/strong> \u2014 renal secretion; kidney-specific isoform of MATE2. Required by FDA, EMA, ICH M12.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Context-dependent transporters \u2014 required under specific conditions<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The following transporters are not universally required but become mandatory when specific conditions apply to your NME:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><th>Transporter<\/th><th>Gene<\/th><th>When required<\/th><th>Agency<\/th><\/tr><tr><td><strong>BSEP<\/strong><\/td><td>ABCB11<\/td><td>All NMEs with hepatic elimination, or any in vitro signal of hepatotoxicity. Although FDA 2020 guideline did not explicitly mention BSEP, ICH, EMA and PMDA all recommend investigation to determine if the drug can inhibit BSEP due to the positive correlation between BSEP inhibition and liver toxicity.<\/td><td>ICH M12, EMA, PMDA (not FDA 2020 explicitly)<\/td><\/tr><tr><td><strong>MRP2<\/strong><\/td><td>ABCC2<\/td><td>Signs of cholestasis or conjugated hyperbilirubinemia in preclinical or clinical data. The International Transporter Consortium recommends that new drug candidates are investigated for MRP2 inhibition if signs of cholestasis or conjugated hyperbilirubinemia surface in clinical trials.<\/td><td>EMA, ITC recommendation<\/td><\/tr><tr><td><strong>OCT1<\/strong><\/td><td>SLC22A1<\/td><td>Hepatic uptake relevant drugs; if OCT1 is a major hepatic uptake pathway. EMA recommends; FDA does not require explicitly.<\/td><td>EMA<\/td><\/tr><tr><td><strong>MRP3, MRP4<\/strong><\/td><td>ABCC3, ABCC4<\/td><td>Hepatic basolateral efflux pathway relevant; if MRP2 is inhibited and compensatory routes matter.<\/td><td>Scientific rationale; no explicit mandate<\/td><\/tr><tr><td><strong>OATP1B1\/1B3 substrate<\/strong><\/td><td>SLC01B1\/1B3<\/td><td>Hepatic metabolism or biliary excretion accounts for \u226525% of drug elimination. Examination of whether an investigational drug is a substrate for OATP1B1 and 1B3 should be considered if hepatic metabolism or biliary excretion accounts for greater than or equal to 25% of elimination.<\/td><td>FDA (ICH M12)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">The cutoff values \u2014 when in vitro data triggers a clinical study<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In vitro inhibition data alone is not always sufficient for regulatory purposes. Each transporter has a defined ratio cutoff: if your compound&#8217;s concentration relative to its IC50 exceeds the cutoff, a clinical DDI study is required to confirm or exclude a clinically meaningful interaction.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><th>Transporter<\/th><th>Inhibitor assessment \u2014 concentration used<\/th><th>Cutoff ratio \u2014 triggers clinical study if exceeded<\/th><\/tr><tr><td><strong>P-gp (intestinal)<\/strong><\/td><td>Total Cmax after highest therapeutic dose<\/td><td>[I] \/ IC50 \u2265 0.1<\/td><\/tr><tr><td><strong>P-gp (systemic)<\/strong><\/td><td>Unbound steady-state Cmax (Cmax,u)<\/td><td>Cmax,u \/ IC50,u \u2265 0.02<\/td><\/tr><tr><td><strong>BCRP (intestinal)<\/strong><\/td><td>Total Cmax after highest therapeutic dose<\/td><td>[I] \/ IC50 \u2265 0.1<\/td><\/tr><tr><td><strong>BCRP (systemic)<\/strong><\/td><td>Unbound steady-state Cmax<\/td><td>Cmax,u \/ IC50,u \u2265 0.02<\/td><\/tr><tr><td><strong>OATP1B1 \/ 1B3<\/strong><\/td><td>Unbound maximum hepatic inlet concentration (Iin,max,u)<\/td><td>R = 1 + (fu,p \u00d7 Iin,max \/ IC50) \u2265 1.1<\/td><\/tr><tr><td><strong>OCT2 \/ OAT1 \/ OAT3<\/strong><\/td><td>Unbound systemic Cmax (Cmax,u)<\/td><td>Cmax,u \/ IC50,u \u2265 0.02<\/td><\/tr><tr><td><strong>MATE1 \/ MATE2-K<\/strong><\/td><td>Unbound systemic Cmax<\/td><td>Cmax,u \/ IC50,u \u2265 0.02<\/td><\/tr><tr><td><strong>BSEP<\/strong><\/td><td>Unbound Cmax in hepatocyte<\/td><td>No universal FDA cutoff; EMA: IC50 below clinical exposure triggers monitoring<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">If your IC50 is comfortably above the clinical exposure (ratio well below cutoff), the in vitro data alone is sufficient for the IND package \u2014 no clinical DDI study required for that transporter. If the ratio approaches or exceeds the cutoff, a clinical study is needed before NDA\/BLA submission.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">FDA vs. EMA vs. ICH M12 \u2014 the key differences<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While the three frameworks are largely aligned, a few practically important differences remain:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BSEP:<\/strong> FDA 2020 guidance does not explicitly list BSEP as a required transporter. ICH M12, EMA, and PMDA do. In practice, BSEP testing is expected for any drug with hepatic involvement \u2014 omitting it creates regulatory risk even in FDA submissions, because reviewers apply ITC recommendations.<\/li>\n\n\n\n<li><strong>OCT1:<\/strong> EMA recommends OCT1 (hepatic uptake, relevant for metformin co-medication); FDA does not explicitly require it. Include in your package if your drug has a hepatic uptake component or targets a metabolic indication where metformin co-medication is likely.<\/li>\n\n\n\n<li><strong>MRP2:<\/strong> EMA recommends routine MRP2 assessment; FDA does not require it unless there is clinical evidence of cholestasis. Pragmatically: if you are testing BSEP (which you should), adding MRP2 to the vesicle assay panel costs little and eliminates a regulatory question.<\/li>\n\n\n\n<li><strong>ICH M12 (2022):<\/strong> Consolidates FDA and EMA into a single harmonised guidance. Use ICH M12 as your primary reference for all new IND packages \u2014 it is the most current and globally applicable standard.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">The complete recommended in vitro transporter panel<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Based on ICH M12, FDA 2020 and EMA 2012, here is the practical panel to include in every IND-enabling DMPK package:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><th>Transporter<\/th><th>Class<\/th><th>Assay format<\/th><th>Priority<\/th><\/tr><tr><td>P-gp (MDR1\/ABCB1)<\/td><td>ABC efflux<\/td><td>Cell-based (substrate) + vesicular (inhibitor\/high Papp)<\/td><td>Mandatory<\/td><\/tr><tr><td>BCRP (ABCG2)<\/td><td>ABC efflux<\/td><td>Cell-based (substrate) + vesicular (inhibitor)<\/td><td>Mandatory<\/td><\/tr><tr><td>OATP1B1<\/td><td>SLC uptake<\/td><td>Transfected cell monolayer<\/td><td>Mandatory<\/td><\/tr><tr><td>OATP1B3<\/td><td>SLC uptake<\/td><td>Transfected cell monolayer<\/td><td>Mandatory<\/td><\/tr><tr><td>OCT2<\/td><td>SLC uptake<\/td><td>Transfected cell monolayer<\/td><td>Mandatory<\/td><\/tr><tr><td>OAT1<\/td><td>SLC uptake<\/td><td>Transfected cell monolayer<\/td><td>Mandatory<\/td><\/tr><tr><td>OAT3<\/td><td>SLC uptake<\/td><td>Transfected cell monolayer<\/td><td>Mandatory<\/td><\/tr><tr><td>MATE1<\/td><td>SLC efflux<\/td><td>Transfected cell monolayer<\/td><td>Mandatory<\/td><\/tr><tr><td>MATE2-K<\/td><td>SLC efflux<\/td><td>Transfected cell monolayer<\/td><td>Mandatory<\/td><\/tr><tr><td>BSEP<\/td><td>ABC efflux<\/td><td>Vesicular transport assay<\/td><td>Strongly recommended (ICH M12, EMA, PMDA)<\/td><\/tr><tr><td>MRP2<\/td><td>ABC efflux<\/td><td>Vesicular transport assay<\/td><td>Recommended (EMA); add if BSEP testing<\/td><\/tr><tr><td>OCT1<\/td><td>SLC uptake<\/td><td>Transfected cell monolayer<\/td><td>Recommended (EMA); add for hepatic drugs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">What happens if you miss a transporter<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Missing a transporter from your IND-enabling package does not automatically result in a clinical hold \u2014 but it generates an Information Request from FDA or a List of Questions from EMA that must be answered before proceeding. In practice, this means:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Months of delay while the missing study is run<\/li>\n\n\n\n<li>Potential for a label restriction if the missing transporter turns out to be clinically relevant (e.g. a statin interaction via OATP1B1 that was not assessed)<\/li>\n\n\n\n<li>Post-marketing commitments to run the missing study after approval \u2014 adding cost and regulatory burden<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The most common omission seen in IND packages: <strong>BSEP<\/strong> (missed because FDA 2020 does not explicitly list it), and <strong>MATE2-K<\/strong> (often bundled with MATE1 but using a non-specific cell system). Both generate routine regulatory questions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">In-house transporter testing with Cell4Pharma vesicle kits<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For the ABC transporter portion of your DMPK package (P-gp inhibitor IC50, BCRP inhibitor IC50, BSEP, MRP2), ready-to-use vesicle kits make in-house testing fast and cost-effective compared to full CRO outsourcing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SeamlessBio distributes the <strong>Cell4Pharma ABC Transporter Vesicle Kit series<\/strong> \u2014 validated, ready-to-use inside-out membrane vesicles for IND-enabling inhibitor characterisation:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/seamlessbio.de\/products\/dmpk-transporter-assays\/bsep-vesicle-kit\/\">BSEP Vesicle Kit<\/a> \u2014 DILI risk assessment, EMA\/PMDA\/ICH M12 recommended<\/li>\n\n\n\n<li><a href=\"https:\/\/seamlessbio.de\/products\/dmpk-transporter-assays\/pgp-vesicle-kit\/\">P-gp Vesicle Kit<\/a> \u2014 MDR1\/ABCB1 inhibitor IC50<\/li>\n\n\n\n<li><a href=\"https:\/\/seamlessbio.de\/products\/dmpk-transporter-assays\/bcrp-vesicle-kit\/\">BCRP Vesicle Kit<\/a> \u2014 ABCG2 inhibitor IC50<\/li>\n\n\n\n<li><a href=\"https:\/\/seamlessbio.de\/products\/dmpk-transporter-assays\/mrp2-vesicle-kit\/\">MRP2 Vesicle Kit<\/a> \u2014 ABCC2; hepatic efflux, cholestasis risk<\/li>\n\n\n\n<li><a href=\"https:\/\/seamlessbio.de\/products\/dmpk-transporter-assays\/mrp1-vesicle-kit\/\">MRP1\u2013MRP5, MRP8 Vesicle Kits<\/a> \u2014 complete MRP panel for comprehensive screening<\/li>\n\n\n\n<li><a href=\"https:\/\/seamlessbio.de\/products\/dmpk-transporter-assays\/control-vesicle-kit\/\">Control Vesicle Kit<\/a> \u2014 non-transfected membrane control for background subtraction<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Each kit: 100 reactions, validated probe substrates, ATP regenerating system, full assay protocol and QC documentation. Stored at \u221280\u00b0C; stable 12 months.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u2192 <a href=\"https:\/\/seamlessbio.de\/products\/dmpk-transporter-assays\/\">View the full Cell4Pharma kit portfolio<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Summary \u2014 the regulatory checklist<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Before your IND package is complete, confirm the following for your NME:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u2705 P-gp \u2014 substrate and inhibitor characterised (cell-based + vesicular where needed)<\/li>\n\n\n\n<li>\u2705 BCRP \u2014 substrate and inhibitor characterised<\/li>\n\n\n\n<li>\u2705 OATP1B1 and OATP1B3 \u2014 inhibitor IC50; substrate if hepatic elimination \u226525%<\/li>\n\n\n\n<li>\u2705 OCT2, OAT1, OAT3 \u2014 inhibitor IC50 determined<\/li>\n\n\n\n<li>\u2705 MATE1 and MATE2-K \u2014 inhibitor IC50 determined<\/li>\n\n\n\n<li>\u2705 BSEP \u2014 inhibitor IC50 assessed (vesicular transport assay)<\/li>\n\n\n\n<li>\u2705 MRP2 \u2014 add if BSEP inhibition observed or hepatic signals present<\/li>\n\n\n\n<li>\u2705 Cutoff ratios calculated for each transporter using clinical Cmax<\/li>\n\n\n\n<li>\u2705 Clinical DDI study triggered where ratio exceeds cutoff<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Further reading on seamlessbio.de:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/seamlessbio.de\/resources\/blog\/vesicular-transport-assay-vs-cell-based-atpase-comparison\/\">Vesicular Transport vs. Cell-Based vs. ATPase Assay \u2014 Which Method?<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/seamlessbio.de\/resources\/blog\/bsep-assay-high-throughput\/\">BSEP Inhibition &amp; DILI \u2014 From Vesicle Assay to High-Throughput Screening<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/seamlessbio.de\/products\/dmpk-transporter-assays\/\">Cell4Pharma ABC Transporter Vesicle Kit Portfolio<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/seamlessbio.de\/applications\/cro-contract-research\/\">CRO &amp; CDMO Biologicals Supply Guide<\/a><\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Questions about your transporter panel or kit selection for IND-enabling studies? Contact us at <a href=\"mailto:info@seamlessbio.de\">info@seamlessbio.de<\/a> or <a href=\"https:\/\/seamlessbio.de\/contact\/\">request a quote<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>August 2026 \u00b7 10 min read Before your drug candidate enters first-in-human trials, regulatory agencies expect you to have characterised its interactions with a defined set of drug transporters. Miss [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-2843","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA &amp; EMA Mandatory Drug Transporters for IND \u2014 DMPK Guide<\/title>\n<meta name=\"description\" content=\"Which transporters are required by FDA, EMA &amp; ICH for IND-enabling studies? Complete regulatory guide: P-gp, BCRP, BSEP, OATPs, OCT2, OAT1\/3, MATEs \u2014 with cutoff values.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA &amp; EMA Mandatory Drug Transporters for IND \u2014 DMPK Guide\" \/>\n<meta property=\"og:description\" content=\"Which transporters are required by FDA, EMA &amp; ICH for IND-enabling studies? Complete regulatory guide: P-gp, BCRP, BSEP, OATPs, OCT2, OAT1\/3, MATEs \u2014 with cutoff values.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T11:48:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-13T12:40:44+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"7\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/cd959a5b0b21c02c26d6ffef79f0d529\"},\"headline\":\"FDA &amp; EMA Mandatory Drug Transporters\",\"datePublished\":\"2026-08-13T11:48:17+00:00\",\"dateModified\":\"2026-08-13T12:40:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/\"},\"wordCount\":1590,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/\",\"name\":\"FDA & EMA Mandatory Drug Transporters for IND \u2014 DMPK Guide\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-08-13T11:48:17+00:00\",\"dateModified\":\"2026-08-13T12:40:44+00:00\",\"description\":\"Which transporters are required by FDA, EMA & ICH for IND-enabling studies? Complete regulatory guide: P-gp, BCRP, BSEP, OATPs, OCT2, OAT1\\\/3, MATEs \u2014 with cutoff values.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA &amp; EMA Mandatory Drug Transporters\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"Place\",\"ProfessionalService\"],\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/#local-main-organization-logo\"},\"address\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/#local-main-place-address\"},\"telephone\":[\"+49 (851) 37932226\"],\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+49 (851) 37932226\",\"email\":\"info@seamlessbio.de\"},\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"},{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Saturday\",\"Sunday\"],\"opens\":\"00:00\",\"closes\":\"00:00\"}],\"email\":\"info@seamlessbio.de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/cd959a5b0b21c02c26d6ffef79f0d529\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/seamlessbio.de\"],\"url\":\"https:\\\/\\\/seamlessbio.de\\\/de\\\/author\\\/admin\\\/\"},{\"@type\":\"PostalAddress\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/#local-main-place-address\",\"streetAddress\":\"Dr.-Ernst-Derra-Str. 4\",\"addressLocality\":\"Passau\",\"postalCode\":\"94036\",\"addressRegion\":\"Bavaria\",\"addressCountry\":\"DE\"},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"width\":973,\"height\":288,\"caption\":\"SeamlessBio\"}]}<\/script>\n<meta name=\"geo.placename\" content=\"Passau\" \/>\n<meta name=\"geo.region\" content=\"Deutschland\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA & EMA Mandatory Drug Transporters for IND \u2014 DMPK Guide","description":"Which transporters are required by FDA, EMA & ICH for IND-enabling studies? Complete regulatory guide: P-gp, BCRP, BSEP, OATPs, OCT2, OAT1\/3, MATEs \u2014 with cutoff values.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/","og_locale":"de_DE","og_type":"article","og_title":"FDA & EMA Mandatory Drug Transporters for IND \u2014 DMPK Guide","og_description":"Which transporters are required by FDA, EMA & ICH for IND-enabling studies? Complete regulatory guide: P-gp, BCRP, BSEP, OATPs, OCT2, OAT1\/3, MATEs \u2014 with cutoff values.","og_url":"https:\/\/seamlessbio.de\/de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/","og_site_name":"SeamlessBio","article_published_time":"2026-08-13T11:48:17+00:00","article_modified_time":"2026-08-13T12:40:44+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"admin","Gesch\u00e4tzte Lesezeit":"7\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/#article","isPartOf":{"@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/"},"author":{"name":"admin","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/cd959a5b0b21c02c26d6ffef79f0d529"},"headline":"FDA &amp; EMA Mandatory Drug Transporters","datePublished":"2026-08-13T11:48:17+00:00","dateModified":"2026-08-13T12:40:44+00:00","mainEntityOfPage":{"@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/"},"wordCount":1590,"commentCount":0,"publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/","url":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/","name":"FDA & EMA Mandatory Drug Transporters for IND \u2014 DMPK Guide","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-08-13T11:48:17+00:00","dateModified":"2026-08-13T12:40:44+00:00","description":"Which transporters are required by FDA, EMA & ICH for IND-enabling studies? Complete regulatory guide: P-gp, BCRP, BSEP, OATPs, OCT2, OAT1\/3, MATEs \u2014 with cutoff values.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"FDA &amp; EMA Mandatory Drug Transporters"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","Place","ProfessionalService"],"@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/#local-main-organization-logo"},"image":{"@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/#local-main-organization-logo"},"address":{"@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/#local-main-place-address"},"telephone":["+49 (851) 37932226"],"contactPoint":{"@type":"ContactPoint","telephone":"+49 (851) 37932226","email":"info@seamlessbio.de"},"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday"],"opens":"09:00","closes":"17:00"},{"@type":"OpeningHoursSpecification","dayOfWeek":["Saturday","Sunday"],"opens":"00:00","closes":"00:00"}],"email":"info@seamlessbio.de"},{"@type":"Person","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/cd959a5b0b21c02c26d6ffef79f0d529","name":"admin","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/seamlessbio.de"],"url":"https:\/\/seamlessbio.de\/de\/author\/admin\/"},{"@type":"PostalAddress","@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/#local-main-place-address","streetAddress":"Dr.-Ernst-Derra-Str. 4","addressLocality":"Passau","postalCode":"94036","addressRegion":"Bavaria","addressCountry":"DE"},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/fda-ema-mandatory-drug-transporters-ind-dmpk-guide\/#local-main-organization-logo","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","width":973,"height":288,"caption":"SeamlessBio"}]},"geo.placename":"Passau","geo.region":"Deutschland"},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/2843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=2843"}],"version-history":[{"count":1,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/2843\/revisions"}],"predecessor-version":[{"id":2844,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/2843\/revisions\/2844"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=2843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/categories?post=2843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/tags?post=2843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}